{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:39:32Z","timestamp":1794461972218,"version":"4.9.1"},"reference-count":53,"publisher":"American Chemical Society (ACS)","issue":"18","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Selective KIT inhibition is an effective strategy for treating mast cell-driven diseases, but highly conserved ATP-binding sites in class III RTKs hinder selective inhibitor design. We employed structure-guided medicinal chemistry to optimize a series of potent, selective KIT inhibitors. An initial triazolopyridine hinge-binding motif enabled potent KIT inhibition with high selectivity and, after central linker optimization, led to a \u201creverse\u201d arylacetamide series with further improved potency and pharmacokinetic properties. Incorporation of a pyrazole-based linker and modification of the hinge-binding motif led to improved potency in the presence of human serum. Further tuning of the terminal aryl substituent mitigated cytochrome P450 time-dependent inhibition and improved kinome selectivity. Crystallography revealed key elements of KIT inhibition and showed that subtle modulation of linker stereoelectronic effects in the gatekeeper region can drive selectivity. These efforts yielded an optimized lead inhibitor with low-nanomolar cellular potency, high KIT selectivity, and properties favorable for chronic therapy.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01334","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:02:14Z","timestamp":1788537734000},"page":"21335-21362","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging Structure-Based Design to Overcome Class III RTK Off-Target Activity in the Development of Selective Wild-Type KIT Inhibitors"],"prefix":"10.1021","volume":"69","author":[{"given":"Hyunyoung","family":"Moon","sequence":"first","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelei","family":"Yan","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8064-8699","authenticated-orcid":true,"given":"Guillaume","family":"Mata","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Wang","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl T.","family":"Haelsig","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G.","family":"Schweickert","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey E.","family":"Sivick","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Ting","family":"Huang","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Van Abbema","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siquan","family":"Chen","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Zhao","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Green","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Jin","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Young","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Walters","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel P.","family":"Walker","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmohan R.","family":"Leleti","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay P.","family":"Powers","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9249-5984","authenticated-orcid":true,"given":"Jenna L.","family":"Jeffrey","sequence":"additional","affiliation":[{"name":"Arcus Biosciences, Inc. , , ,","place":["Hayward, California, United States, 94545"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"2026092315264069800_cit1","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jaci.2022.04.012","article-title":"KIT as a master regulator of the mast cell lineage","volume":"149","author":"Tsai","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026092315264069800_cit2","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-KIT: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol. Rev."},{"key":"2026092315264069800_cit3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-021-00622-y","article-title":"Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases","volume":"22","author":"Kolkhir","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"2026092315264069800_cit4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/187152807780077255","article-title":"Targeting Kit Activation: A Potential Therapeutic Approach in the Treatment of Allergic Inflammation","volume":"6","author":"Jensen","year":"2007","journal-title":"Inflamm Allergy Drug Targets"},{"key":"2026092315264069800_cit5","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/all.15262","article-title":"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study","volume":"77","author":"Alvarado","year":"2022","journal-title":"Allergy"},{"key":"2026092315264069800_cit6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/all.15585","article-title":"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Terhorst-Molawi","year":"2023","journal-title":"Allergy"},{"key":"2026092315264069800_cit7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.chembiol.2018.11.005","article-title":"What makes a kinase promiscuous for inhibitors?","volume":"26","author":"Hanson","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"2026092315264069800_cit8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"2026092315264069800_cit9","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-10-1124","article-title":"New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects","volume":"10","author":"Aparicio-Gallego","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"2026092315264069800_cit10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Sunder","year":"2023","journal-title":"Signal Transduction Targeted Ther."},{"issue":"2","key":"2026092315264069800_cit11","doi-asserted-by":"publisher","first-page":"AB62","DOI":"10.1016\/j.jaci.2023.11.215","article-title":"BLU-808, a Potent and Selective Small Molecule Inhibitor of Wild-type c-KIT for Mast Cell Disorders","volume":"153","author":"Grassian","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"2026092315264069800_cit12","doi-asserted-by":"publisher","first-page":"AB171","DOI":"10.1016\/j.jaci.2024.12.540","article-title":"BLU-808: A Potent and Selective Oral Small Molecule Wild-Type KIT Tyrosine Kinase Inhibitor for Allergic Conditions","volume":"155","author":"Hatlen","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026092315264069800_cit13","unstructured":"Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) (NCT06931405) 2026\n          https:\/\/clinicaltrials.gov\/study\/NCT06931405. (Accessed June 6, 2026)."},{"key":"2026092315264069800_cit14","unstructured":"BioSpace. Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria2022. https:\/\/www.biospace.com\/third-harmonic-bio-announces-discontinuation-of-phase-1b-study-of-thb001-in-chronic-inducible-urticaria."},{"key":"2026092315264069800_cit15","unstructured":"Third Harmonic Bio, Inc.\n          2023, Form 10-K.; SEC. https:\/\/www.sec.gov\/edgar\/browse\/?CIK=0001923840."},{"issue":"2","key":"2026092315264069800_cit16","doi-asserted-by":"publisher","first-page":"No. AB35","DOI":"10.1016\/j.jaci.2025.12.110","article-title":"Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated Diseases","volume":"157","author":"Roqueta-Rivera","year":"2026","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026092315264069800_cit17","unstructured":"ClinicalTrials.gov. A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults, https:\/\/clinicaltrials.gov\/study\/NCT07540910. (Accessed June 11, 2026)."},{"key":"2026092315264069800_cit18","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.jacig.2024.100249","article-title":"A highly selective KIT inhibitor MOD000001 suppresses IgE-mediated mast cell activation","volume":"3","author":"Nakamura","year":"2024","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"2026092315264069800_cit19","doi-asserted-by":"publisher","first-page":"31461","DOI":"10.1074\/jbc.C300186200","article-title":"Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation","volume":"278","author":"Mol","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2026092315264069800_cit20","doi-asserted-by":"publisher","first-page":"31655","DOI":"10.1074\/jbc.M403319200","article-title":"Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase","volume":"279","author":"Mol","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2026092315264069800_cit21","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1073\/pnas.0812413106","article-title":"KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients","volume":"106","author":"Gajiwala","year":"2009","journal-title":"PNAS"},{"key":"2026092315264069800_cit22","doi-asserted-by":"publisher","first-page":"5689","DOI":"10.1073\/pnas.1219457110","article-title":"Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor","volume":"110","author":"Zhang","year":"2013","journal-title":"PNAS"},{"key":"2026092315264069800_cit23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41467-023-44376-8","article-title":"Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA","volume":"15","author":"Teuber","year":"2024","journal-title":"Nat. Commun."},{"key":"2026092315264069800_cit25","doi-asserted-by":"publisher","first-page":"10:995351","DOI":"10.3389\/fchem.2022.995351","article-title":"Urea-based anticancer agents. Exploring 100-years of research with an eye to the future","volume":"10","author":"Listro","year":"2022","journal-title":"Front. Chem."},{"key":"2026092315264069800_cit26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/app11010374","article-title":"Diarylureas as Antitumor Agents","volume":"11","author":"Catalano","year":"2021","journal-title":"Appl. Sci."},{"key":"2026092315264069800_cit27","doi-asserted-by":"publisher","first-page":"9450","DOI":"10.3390\/ijms24119450","article-title":"Small Molecule c-KIT Inhibitors for the Treatment of Gastrointestinal Stromal Tumors: A Review on Synthesis, Design Strategies, and Structure\u2212Activity Relationship (SAR)","volume":"24","author":"Godesi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"2026092315264069800_cit28","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1021\/jm100301x","article-title":"Analysis of Kinase Inhibitor Selectivity using a Thermodynamics-Based Partition Index","volume":"53","author":"Cheng","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026092315264069800_cit29","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1016\/j.bmc.2015.08.006","article-title":"Kinase hinge binding scaffolds and their hydrogen bond patterns","volume":"23","author":"Xing","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"2026092315264069800_cit30","doi-asserted-by":"publisher","first-page":"102247","DOI":"10.1016\/j.jbc.2022.102247","article-title":"Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors","volume":"298","author":"Arter","year":"2022","journal-title":"J. Biol. Chem."},{"key":"2026092315264069800_cit31","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1021\/acsmedchemlett.3c00212","article-title":"How Ligands Interact with the Kinase Hinge","volume":"14","author":"Zhao","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"2026092315264069800_cit33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"2026092315264069800_cit35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026092315264069800_cit36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026092315264069800_cit38","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.chembiol.2010.09.010","article-title":"Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry","volume":"17","author":"Wodicka","year":"2010","journal-title":"Chem. Biol."},{"key":"2026092315264069800_cit39","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"2026092315264069800_cit40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2026092315264069800_cit41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s1097-2765(03)00505-7","article-title":"The structural basis for autoinhibition of FLT3 by the juxtamembrane domain","volume":"13","author":"Griffith","year":"2004","journal-title":"Mol. Cell"},{"key":"2026092315264069800_cit42","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1182\/blood-2005-06-2596","article-title":"Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML","volume":"107","author":"Reindl","year":"2006","journal-title":"Blood"},{"key":"2026092315264069800_cit43","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1182\/bloodadvances.2020002876","article-title":"Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis","volume":"5","author":"Young","year":"2021","journal-title":"Blood Adv."},{"key":"2026092315264069800_cit44","article-title":"A novel cell-based assay to identify the FLT3 kinase construct used in enzyme assays that best represents the activity of cellular FLT3","volume-title":"Presented at the SLAS2024 International Conference and Exhibition","author":"Shen","year":"2024"},{"key":"2026092315264069800_cit45","doi-asserted-by":"publisher","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"PNAS"},{"key":"2026092315264069800_cit46","unstructured":"Sino Biological product datasheet.\n          https:\/\/cdn1.sinobiological.com\/datasheet\/signaling\/K06-11BG\/A4681-9.pdf (Accessed Apr 16, 2026)."},{"key":"2026092315264069800_cit47","unstructured":"ProQinase (Reaction Biology Europe) product datasheet.\n          https:\/\/www.proqinase.com\/sites\/default\/files\/public\/kit_lot011_coa_v2.pdf (Accessed Apr 16, 2026)."},{"key":"2026092315264069800_cit48","unstructured":"Sino Biological product datasheet.\n          https:\/\/cdn1.sinobiological.com\/datasheet\/signaling\/P12-18G\/U4817-6.pdf (Accessed Apr 16, 2026)."},{"key":"2026092315264069800_cit49","unstructured":"ThermoFisher product page.\n          https:\/\/www.thermofisher.com\/proteins\/product\/Human-PDGFRA-PDGFR-alpha-GST-Tag-Recombinant-Protein\/PV3811 (Accessed Apr 16, 2026)."},{"key":"2026092315264069800_cit50","unstructured":"Sino Biological product page.\n          https:\/\/www.sinobiological.com\/recombinant-proteins\/human-pdgfrb-p13-11g-scb (Accessed Apr 16, 2026)."},{"key":"2026092315264069800_cit51","unstructured":"ThermoFisher product page.\n          https:\/\/www.thermofisher.com\/proteins\/product\/PV3591.html (Accessed Apr 16, 2026)."},{"key":"2026092315264069800_cit52","unstructured":"Sino Biological product page.\n          https:\/\/www.sinobiological.com\/recombinant-proteins\/human-csf1r-c74-11g-scb (Accessed Apr 16, 2026)."},{"key":"2026092315264069800_cit53","unstructured":"Fisher Scientific product page.\n          https:\/\/www.fishersci.com\/shop\/products\/csf1r-fms-recombinant-human-protein-4\/PV3249 (Accessed Apr 16, 2026)."},{"key":"2026092315264069800_cit54","unstructured":"Sino Biological product page.\n          https:\/\/www.sinobiological.com\/recombinant-proteins\/human-flt3-f12-11g-scb (Accessed Apr 16, 2026)."},{"key":"2026092315264069800_cit55","unstructured":"ThermoFisher product page.\n          https:\/\/www.thermofisher.com\/proteins\/product\/Human-FLT3-His-Tag-Recombinant-Protein\/PV4108 (Accessed Apr 16, 2026)."},{"key":"2026092315264069800_cit58","doi-asserted-by":"publisher","first-page":"18553","DOI":"10.1021\/acs.jmedchem.6c00898","article-title":"Discovery of a potent, orally bioavailable small-molecule inhibitor of wildtype KIT with exceptionally high kinome selectivity","volume":"69","author":"Chen","year":"2026","journal-title":"J. Med. Chem."},{"key":"2026092315264069800_cit67","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nbt.2017","article-title":"Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity","volume":"29","author":"Anastassiadis","year":"2011","journal-title":"Nat. Biotechnol."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01334","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/18\/21335\/68626533\/jm6c01334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/18\/21335\/68626533\/jm6c01334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:21:18Z","timestamp":1794457278000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/18\/21335\/5420904\/Leveraging-Structure-Based-Design-to-Overcome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":53,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9,4]]},"published-print":{"date-parts":[[2026,9,24]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01334","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01334.s004","asserted-by":"subject"}]},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}